Day: December 9, 2019

Results presented at 61st ASH Annual Conference in Orlando, FL, USASignals of clinical efficacy continue to be encouraging, with 75% OR (6 out of 8: 2 CR, 3 CRi and 1 PR)Rapid clinical responses (mean time to first response is currently 32 days)Preliminary rate of conversion to red cell Transfusion Independence (40%) is also encouragingSafe and well tolerated, with no clinically relevant non-hematological AEsMADRID, Spain and CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presented new data from its ongoing Phase II trial ALICE, which is investigating iadademstat in combination with azacitidine in elderly patients with acute myeloid...

Spring Hope, NC, Dec. 09, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Hemp, Inc. (OTC PINK: HEMP) a global leader in the industrial hemp industry with bi-coastal processing centers, including the largest multipurpose industrial hemp processing facility in the western hemisphere, announced today news coverage in the outlet, CEOCFO Magazine, an independent investment publication that highlights important technologies and companies.The published article features an interview with Bruce Perlowin, CEO of Hemp, Inc., regarding a wide variety of topics, ranging from the history of Hemp, Inc., the uses of hemp and the current size of the industrial hemp market. There is also commentary on Hemp, Inc.’s industrial materials, the difference between marijuana and hemp, the Company’s growth and geographic reach. Additionally, the interview...

Banca IFIS Group presentsthe three-year Business Plan                                                                                         Milan, 9th December 2019 – Luciano Colombini, Banca IFIS’s CEO, is pleased to invite you to attend the presentation of 2020-2022 Business Plan that will take place:Tuesday, 14th January 2020at 11:00 CET Excelsior Hotel GalliaPiazza Duca d’Aosta, 9 – MilanQ&A session. The presentation will be followed by a Q&A session.After presentation a light lunch.Live Stream. If you are unable to attend, it will be possible to follow the event via live stream.Presentation material. The slide presentation will be available for downloading on our website https://www.bancaifis.it/ in the Investor Relations section, shortly before the beginning of the event.                                                                                                           Attachment20191209_Banca...

Il Gruppo Banca IFISpresenta il Piano Industriale triennale                                                                                         Milano, 09 Dicembre 2019 – Luciano Colombini, amministratore delegato di Banca IFIS S.p.A., è lieto di invitare la comunità finanziaria alla presentazione del Piano Industriale 2020/2022 che si terrà:Martedì, 14 Gennaio 2020alle ore 11:00 Excelsior Hotel GalliaPiazza Duca d’Aosta, 9 – MilanoQ&A. Al termine della presentazione è prevista una Q&A session.A seguire light lunch.Diretta Live. In caso di impossibilità a partecipare, sarà possibile seguire l’evento in diretta live.Materiali. Le slide della presentazione saranno disponibili per la consultazione e il download sul sito https://www.bancaifis.it/ alla sezione Investor Relations, poco prima dell’inizio dell’evento.                                                                                                           Allegato20191209_Banca...

CARGOTEC CORPORATION, PRESS RELEASE, 9 DECEMBER 2019 AT 05:10 PM (EET)Navis, a part of Cargotec Corporation, and the provider of operational technologies and services that unlock greater performance and efficiency for the world’s leading organisations across the shipping supply chain, has entered into an agreement to acquire the assets of Jade Logistics, a provider of the Master Terminal TOS for mixed cargo terminals. Jade Logistics is based in Christchurch, New Zealand and is trusted by over 100 facilities globally to manage the transport of mixed cargo such as steel, timber, containers, cars and many other materials. With N4, Octopi and Jade Master Terminal, Navis can offer the flexibility of the right TOS for any prospective customer’s cargo requirements. Navis will establish a General Cargo Center of Excellence in Christchurch, New...

CARGOTEC OYJ, LEHDISTÖTIEDOTE, 9. JOULUKUUTA 2019 KLO 17:10Cargoteciin kuuluva Navis on sopinut ostavansa Christchurchissa Uudesta-Seelannissa toimivan Jade Logistics -yhtiön liiketoiminnot. Yhtiön sekarahtiterminaaleille tarkoitettua Master Terminal -toiminnanohjausjärjestelmää (TOS) käytetään yli 100 terminaalissa globaalisti sekarahdin, kuten teräksen, puun, konttien ja autojen hallintaan. Navis voi N4-, Octopi- ja Jade Master Terminal -tuotteidensa avulla tarjota juuri oikeanlaisen toiminnanohjausjärjestelmän erityyppisten asiakkaiden lastinkäsittelytarpeisiin. Navis perustaa General Cargo Center of Excellence -keskuksen Christchurchiin palvelemaan kasvavaa sekarahtiratkaisujen kysyntää maailmanlaajuisesti. Kaupan odotetaan toteutuvan vuoden 2019 loppuun mennessä.Jade Logisticsin oston myötä Navis pystyy entistä paremmin tukemaan ympäri...

— Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 —— Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET —MENLO PARK, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced preclinical proof-of-concept data for its novel all antibody conditioning regimen, comprised of FSI-174, its anti-cKIT antibody, and magrolimab, its anti-CD47 antibody. Preclinical studies in a non-human primate (NHP) model showed that the combination of FSI-174 and magrolimab significantly depleted hematopoietic stem cells (HSCs) from the bone marrow, with no dose limiting toxicities. The data will be presented in a poster session...

– Robust Hemoglobin Increases Maintained in 18 Patients in the Extension Phase of the Study with Median Treatment Duration of Three Years –– Cumulative Safety Profile (Core Period plus Extension Phase) Continues to Support Long-term Twice Daily Dosing of Mitapivat –– Data from the Natural History Study Demonstrate that PK Deficiency Patients, Regardless of Transfusion Status, Have Higher Rates of Select Comorbidities and Complications –– Company to Host Investor Event and Webcast Today at 8:00 p.m. ET –ORLANDO, Fla., Dec. 09, 2019 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported new data from the extension phase of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency at the...

61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP studyTab-cel® was generally well-tolerated in all patients with EBV+ PTLD and other EBV-associated diseasesEstimated two-year overall survival rate in tab-cel® responders was 86 and 100 percent for patients with EBV+ PTLD following HCT and SOT, respectively, with median time to response of one monthSimilar outcomes observed in subgroup of 22 patients with EBV+ PTLD who would have likely met eligibility criteria for Atara’s ongoing tab-cel®Phase 3 studiesSOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer,...

STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that its collaborator, GlaxoSmithKline, presented data evaluating SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat (formerly PF-03084014), alone and in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in preclinical cell line models of human multiple myeloma and other lymphomas. The data demonstrated that treatment of BCMA-expressing cancer cell lines with nirogacestat led to significantly increased levels of cell surface expression of BCMA and...